IBA Notice of Half Year 2022 Results and Conference Call

Corporate
/
11.07.2022

HY22 results meeting to take place as a hybrid event on Wednesday, 31 August 2022 at 3pm CEST

Louvain-la-Neuve, Belgium, 11 July 2022 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today that it will publish its consolidated results for the half year 2022 on Wednesday, 31 August 2022 at 7am CEST.

Conference Call Information
Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host a hybrid event, including a conference call and webcast, conducted in English, to present the half year results, followed by a Q&A session.

The conference call will be held on Wednesday,31 August 2022 at 3pm CEST / 2pm BST / 9am EDT / 6amPDT as a Teams webinar and can be accessed online on this link.

If you would like to join by phone only, please dial (Phone conference ID 495 140 424#):

Belgium:                     +32 2 890 97 20

UK:                             +44 20 3321 5200

NL:                              +31 20 708 6901

LU:                              +352 27 87 00 02

US:                             +1 347-991-7591

FR:                              +33 1 70 99 53 51

The presentation will be available on IBA’s investor relations website and on:
https://www.iba-worldwide.com/content/iba-half-year-results-2022-press-release-and-presentation  shortly before the call.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast. 

For participants who do not have the Teams application installed, please follow the process described in this link to access the conference.

ENDS

About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,700 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

 

Share
Download

Cookies policy

En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour vous proposer des services et des offres adaptés à vos centres d’intérêts.

Gérer vos préférences de cookies

Chez IBA, le respect de votre vie privée reste une priorité.

Les cookies fonctionnels garantissent le fonctionnement du site web. Ils ne peuvent pas être désactivés. En réglant vos préférences, vous pouvez activer et désactiver l’utilisation de ces cookies sur notre site web. Ces réglages ne seront valides que sur l’appareil que vous utilisez actuellement.

Cookies policies